nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.10.2014 | Original Article – Cancer Research

miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells

verfasst von: Mengru Cao, Yulian Li, Hailing Lu, Qingwei Meng, Long Wang, Li Cai, Xiaoqun Dong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the interaction between insulin receptor substrate-1 (IRS-1) and miR-23a on the migration and invasion of non-small cell lung cancer (NSCLC) cells, and to examine IRS-1 expression in NSCLC tissues and its correlation with clinicopathologic characteristics.

Methods

The migration and invasion of A549 cells were measured using transwell assay. miR-23a levels were examined by quantitative reverse transcription-PCR and IRS-1 expression by Western blotting. The interaction between miR-23a and IRS-1 was examined by luciferase reporter assay. IRS-1 expression in 105 NSCLC specimens was determined by immunohistochemistry and its correlation with patient clinicopathologic characteristics was evaluated.

Results

Transwell assay revealed that miR-23a significantly promoted the migration and invasion of A549 cells with a 44.0 and 44.6 % increase in the number of migrated and invading cells, respectively. Luciferase assay showed that miR-23a markedly reduced luciferase activities of A549 cells co-transfected with plasmids overexpressing the 3′ UTR of IRS-1 mRNA (P < 0.05). Co-transfection of A549 cells with miR-23a and plasmids overexpressing IRS-1 significantly reduced the increase in the number of migrated and invading cells mediated by miR-23a. Immunohistochemistry showed low IRS-1 expression in 26.7 % and high IRS-1 expression in 73.3 % of the NSCLC specimens. Kaplan–Meier analysis revealed that the overall survival and disease-free survival of NSCLC were markedly longer in patients with high IRS-1 expression than those with low IRS-1 expression (P = 0.002). Multivariate Cox regression analysis showed that IRS-1 was an independent prognostic factor for the overall survival of NSCLC patients (RR 0.413 CI 0.238–0.718, P = 0.002).

Conclusions

There is an interaction between miR-23a and IRS-1 in the modulation of the migration and invasion of NSCLC cells. IRS-1 is variably expressed in NSCLC patients and correlates with NSCLC patient survival.

Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169–193PubMedCrossRef

Cao M, Seike M, Soeno C, Mizutani H, Kitamura K et al (2012) MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 41:869–875PubMedPubMedCentral

Chekulaeva M, Filipowicz W (2009) Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21:452–460PubMedCrossRef

Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH et al (2006) Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 66:5304–5313PubMedCrossRef

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762–765PubMedCrossRefPubMedCentral

Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60:167–179PubMedCrossRef

Gibson SL, Ma Z, Shaw LM (2007) Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 6:631–637PubMedCrossRef

Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99–109PubMedCrossRef

Han CH, Cho JY, Moon JT, Kim HJ, Kim SK et al (2006) Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. Oncol Rep 16:1205–1210PubMed

Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K et al (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65:9628–9632PubMedCrossRef

Huang S, He X, Ding J, Liang L, Zhao Y et al (2008) Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 123:972–978PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120:635–647PubMedCrossRef

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI et al (2008) Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat 111:79–91PubMedCrossRef

Luo X, Fan S, Huang W, Zhai S, Ma Z et al (2012) Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma. Oncol Rep 28:659–667PubMed

Ma Z, Gibson SL, Byrne MA, Zhang J, White MF et al (2006) Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26:9338–9351PubMedCrossRefPubMedCentral

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef

Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L et al (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24PubMedCrossRefPubMedCentral

Moran C (2011) Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 178:1940–1948PubMedCrossRefPubMedCentral

Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323PubMedCrossRef

Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B et al (2009) MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 16:1047–1061PubMedCrossRef

Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK et al (2000) IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19:2687–2694PubMedCrossRef

Saintigny P, Burger JA (2012) Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13:287–297PubMed

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef

Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J et al (2000) Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89:506–513PubMedCrossRef

Shi J, Wang DM, Wang CM, Hu Y, Liu AH et al (2009) Insulin receptor substrate-1 suppresses transforming growth factor-beta1-mediated epithelial-mesenchymal transition. Cancer Res 69:7180–7187PubMedCrossRef

Tang HL, Deng M, Liao QJ, Zeng X, Zhou XT et al (2012) Expression and clinical significance of miR-23a and metastasis suppressor 1 in colon carcinoma. Zhonghua Bing Li Xue Za Zhi 41:28–32PubMed

Tsim S, O’Dowd CA, Milroy R, Davidson S (2010) Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 104:1767–1774PubMedCrossRef

White MF (2003) Insulin signaling in health and disease. Science 302:1710–1711PubMedCrossRef

Xia H, Ooi LL, Hui KM (2013) MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198PubMedCrossRef

Titel: miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells
verfasst von: Mengru Cao
Yulian Li
Hailing Lu
Qingwei Meng
Long Wang
Li Cai
Xiaoqun Dong
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1725-0

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients

The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

Dynamics of fertility impairment in childhood brain tumour survivors

Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells

Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie